Article
Lasofoxifene as a potential treatment for therapy-resistant ER-positive metastatic breast cancer.
Breast cancer research : BCR - 12 May 2021
Lainé Muriel, Fanning Sean W, Chang Ya-Fang, Green Bradley, Greene Marianne E, Komm Barry, Kurleto Justyna D, Phung Linda, Greene Geoffrey L
Abstract excerpt
BACKGROUND: Endocrine therapy remains the mainstay of treatment for estrogen receptor-positive (ER+) breast cancer. Constitutively active mutations in the ligand binding domain of ERα render tumors resistant to endocrine agents. Breast cancers with the two most common ERα mutations, Y537S and D538G, have low sensitivity to fulvestrant inhibition, a typical second-line endocrine therapy. Lasofoxifene is a...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.